210 related articles for article (PubMed ID: 38474199)
21. Chronic inflammatory changes and oxidative stress in the background of "pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasm".
Matsuda R; Miyasaka Y; Yamada Y; Kawata J; Sakihama K; Yamamoto T; Saeki K; Yamamoto H; Ohishi Y; Koga Y; Nakamura M; Oda Y
Virchows Arch; 2020 Dec; 477(6):799-806. PubMed ID: 32468246
[TBL] [Abstract][Full Text] [Related]
22. Of immune checkpoint maladies and remedies: The throwing of jabs in the oncogenic ring of PDAC.
Olaoba OT; Ligali FC; Alabi ZO; Akinyemi AO; Ayinde KS
Biochim Biophys Acta Rev Cancer; 2021 Jan; 1875(1):188483. PubMed ID: 33232723
[TBL] [Abstract][Full Text] [Related]
23. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
24. GaWRDenMap: a quantitative framework to study the local variation in cell-cell interactions in pancreatic disease subtypes.
Krishnan SN; Mohammed S; Frankel TL; Rao A
Sci Rep; 2022 Mar; 12(1):3708. PubMed ID: 35260589
[TBL] [Abstract][Full Text] [Related]
25. [Intraepithelial neoplasms (PanIN) and intraductal papillary-mucinous neoplasms (IPMN) of the pancreas as precursor lesions of pancreatic carcinoma].
Ott C; Heinmöller E; Gaumann A; Schölmerich J; Klebl F
Med Klin (Munich); 2007 Feb; 102(2):127-35. PubMed ID: 17323019
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
[TBL] [Abstract][Full Text] [Related]
27. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
[TBL] [Abstract][Full Text] [Related]
28. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
[TBL] [Abstract][Full Text] [Related]
29. Incidentally discovered pancreatic intraepithelial neoplasia: what is its clinical significance?
Konstantinidis IT; Vinuela EF; Tang LH; Klimstra DS; D'Angelica MI; Dematteo RP; Kingham TP; Fong Y; Jarnagin WR; Allen PJ
Ann Surg Oncol; 2013 Oct; 20(11):3643-7. PubMed ID: 23748606
[TBL] [Abstract][Full Text] [Related]
30. Outcomes of Neoadjuvant Chemotherapy for Invasive Intraductal Papillary Mucinous Neoplasm Compared with de Novo Pancreatic Adenocarcinoma.
Fogliati A; Zironda A; Fiorentini G; Adjei S; Amro A; Starlinger PP; Grotz TE; Warner SG; Smoot RL; Thiels CA; Kendrick ML; Cleary SP; Truty MJ
Ann Surg Oncol; 2024 Apr; 31(4):2632-2639. PubMed ID: 38319513
[TBL] [Abstract][Full Text] [Related]
31. PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC.
Wang X; Li X; Wei X; Jiang H; Lan C; Yang S; Wang H; Yang Y; Tian C; Xu Z; Zhang J; Hao J; Ren H
Signal Transduct Target Ther; 2020 Apr; 5(1):38. PubMed ID: 32300119
[TBL] [Abstract][Full Text] [Related]
32. Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception.
Hernandez S; Parra ER; Uraoka N; Tang X; Shen Y; Qiao W; Jiang M; Zhang S; Mino B; Lu W; Pandurengan R; Haymaker C; Affolter K; Scaife CL; Yip-Schneider M; Schmidt CM; Firpo MA; Mulvihill SJ; Koay EJ; Wang H; Wistuba II; Maitra A; Solis LM; Sen S
Clin Cancer Res; 2022 May; 28(9):1938-1947. PubMed ID: 35491652
[TBL] [Abstract][Full Text] [Related]
33. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma.
Ene-Obong A; Clear AJ; Watt J; Wang J; Fatah R; Riches JC; Marshall JF; Chin-Aleong J; Chelala C; Gribben JG; Ramsay AG; Kocher HM
Gastroenterology; 2013 Nov; 145(5):1121-32. PubMed ID: 23891972
[TBL] [Abstract][Full Text] [Related]
34. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic cancer.
Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
[TBL] [Abstract][Full Text] [Related]
35. Dynamic profiling of immune microenvironment during pancreatic cancer development suggests early intervention and combination strategy of immunotherapy.
Yang J; Zhang Q; Wang J; Lou Y; Hong Z; Wei S; Sun K; Wang J; Chen Y; Sheng J; Su W; Bai X; Liang T
EBioMedicine; 2022 Apr; 78():103958. PubMed ID: 35316682
[TBL] [Abstract][Full Text] [Related]
36. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
[TBL] [Abstract][Full Text] [Related]
37. Annexin A10 is a candidate marker associated with the progression of pancreatic precursor lesions to adenocarcinoma.
Zhu J; Wu J; Pei X; Tan Z; Shi J; Lubman DM
PLoS One; 2017; 12(4):e0175039. PubMed ID: 28369074
[TBL] [Abstract][Full Text] [Related]
38. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
39. Hepatic myofibroblasts exert immunosuppressive effects independent of the immune checkpoint regulator PD-L1 in liver metastasis of pancreatic ductal adenocarcinoma.
Beckinger S; Daunke T; Aldag L; Krüger S; Heckl S; Wesch D; Schäfer H; Röcken C; Rahn S; Sebens S
Front Oncol; 2023; 13():1160824. PubMed ID: 37207152
[TBL] [Abstract][Full Text] [Related]
40. Expression of SNAIL in accompanying PanIN is a key prognostic indicator in pancreatic ductal adenocarcinomas.
Fujiwara S; Saiki Y; Ishizawa K; Fukushige S; Yamanaka M; Sato M; Ishida M; Motoi F; Unno M; Horii A
Cancer Med; 2019 Apr; 8(4):1671-1678. PubMed ID: 30791220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
